Gilead Sciences Inc. reported $1.26 million in lobbying spending in the three months ending June 30, according to Monday disclosures with the U.S.
Congress. That was up 17% from a year ago and came as U.S. officials in May issued an emergency use authorization for Gilead’s remdesivir as a treatment for Covid-19 after a trial found it sped recovery by about four days in hospitalized patients.Gilead donated remdesivir to hospitals through June, but the company announced at the close of that month its plans to charge $390 a vial, or $2,340 for a five-day regimen, for direct government purchases by the U.S.
or other developed countries.London-based AstraZeneca Plc spent $780,000 as the company raced to develop a vaccine to protect against the.